A multinational pharmaceutical company is seeking first-in-class novel/established drug targets for Targeted Protein Degradation (TPD), especially proteolysis-targeting chimeras (PROTACs) in oncology. Priority cancers of interest are biliary tract cancer, pancreatic cancer, non-small cell lung cancer (PD-L1 negative), prostate cancer (castration-resistant), urothelial cancer, acute myeloid leukaemia. Other cancers such as breast cancer (triple-negative), ovarian cancer (platinum-resistant), soft tissue sarcoma and diffuse large B-cell lymphoma are also of...
Oncology Drug Targets Exploiting Targeted Protein Degradation (TPD)
Opportunity types being sought:
-
Technology
-
Academic Researcher
-
Centre of Excellence
-
Research Project
-
Spinout Company
To see the full details and submit your response please register now.
Benefits of registration:
- Receive updates on the latest industry calls
- Quickly and easily respond to calls via your dashboard
- Build your academic profile
Opportunity types being sought:
-
Technology
-
Academic Researcher
-
Centre of Excellence
-
Research Project
-
Spinout Company